582 related articles for article (PubMed ID: 26856585)
1. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
[TBL] [Abstract][Full Text] [Related]
2. Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease.
Ko JY; Wang FS; Lian WS; Yang FS; Chen JW; Huang PH; Liao CY; Kuo SJ
Mol Med; 2024 May; 30(1):66. PubMed ID: 38773377
[TBL] [Abstract][Full Text] [Related]
3. An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases.
Brunetti G; D'Amato G; Chiarito M; Tullo A; Colaianni G; Colucci S; Grano M; Faienza MF
World J Pediatr; 2019 Feb; 15(1):4-11. PubMed ID: 30343446
[TBL] [Abstract][Full Text] [Related]
4. Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals.
Korkosz M; Czepiel M; Guła Z; Stec M; Węglarczyk K; Rutkowska-Zapała M; Gruca A; Lenart M; Baran J; Gąsowski J; Błyszczuk P; Siedlar M
BMC Musculoskelet Disord; 2018 Dec; 19(1):434. PubMed ID: 30522483
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the bone turnover markers dickkopf-1, osteoprotegerin, and TNF-α in knee osteoarthritis patients.
Min S; Wang C; Lu W; Xu Z; Shi D; Chen D; Teng H; Jiang Q
Clin Rheumatol; 2017 Oct; 36(10):2351-2358. PubMed ID: 28676900
[TBL] [Abstract][Full Text] [Related]
6. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
[TBL] [Abstract][Full Text] [Related]
7. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
8. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
[TBL] [Abstract][Full Text] [Related]
9. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
[TBL] [Abstract][Full Text] [Related]
10. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
11. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
14. Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.
D'Eufemia P; Finocchiaro R; Zambrano A; Lodato V; Celli L; Finocchiaro S; Persiani P; Turchetti A; Celli M
Osteoporos Int; 2017 Jan; 28(1):339-346. PubMed ID: 27562566
[TBL] [Abstract][Full Text] [Related]
15. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn's patients via bone formation and bone resorption.
Blaschke M; Koepp R; Cortis J; Komrakova M; Schieker M; Hempel U; Siggelkow H
Adv Clin Exp Med; 2018 Jan; 27(1):45-56. PubMed ID: 29521042
[TBL] [Abstract][Full Text] [Related]
16. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures.
Giganti MG; Liuni F; Celi M; Gasbarra E; Zenobi R; Tresoldi I; Modesti A; Bei R; Tarantino U
J Biol Regul Homeost Agents; 2012; 26(4):671-80. PubMed ID: 23241117
[TBL] [Abstract][Full Text] [Related]
18. Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts.
Lee DW; Kwon JY; Kim HK; Lee HJ; Kim ES; Kim HJ; Kim HJ; Lee HB
Int J Med Sci; 2018; 15(7):723-729. PubMed ID: 29910677
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
20. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.
Lee JS; Ryu CH; Moon NH; Kim SJ; Park SY; Suh KT
Arch Orthop Trauma Surg; 2009 May; 129(5):711-8. PubMed ID: 18427820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
